Dizlin Pharmaceuticals

Executive Summary

Dizlin Pharmaceuticals AB is a Swedish research company focused on developing novel, stable levodopa-carbidopa solutions for continuous subcutaneous and intravenous infusion to treat motor fluctuations in advanced Parkinson's disease. The company's core technology addresses the limitations of oral therapies by providing steady drug delivery, potentially improving quality of life for patients. Dizlin operates on a business model centered on product development and licensing to established pharmaceutical partners, positioning itself as a technology enabler rather than a commercial manufacturer. As a private, early-stage company, Dizlin's value is tied to achieving key development milestones and securing strategic partnerships. Its progress is contingent on successful preclinical and clinical validation of its infusion platform.

Upcoming Catalysts (preview)

• Q1 2027Initiation of First-in-Human Phase 1 Trial for Subcutaneous Levodopa-Carbidopa Infusion60% success
• Q2 2027Licensing Deal with a Mid-Size or Large Pharmaceutical Partner40% success
• Q4 2026Completion of Preclinical Toxicology Studies Supporting IND Filing80% success